Fund moves
264KShares reported
12 tracked managers disclosed the same change for Q3 2025. Among this manager's largest new positions for Q3 2025.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 19, 2025 · Filed Sep 22, 2025
A major shareholder of Eli Lilly sold $17.5M of Eli Lilly shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$17,523,512
Shares × reported transaction price
43 days after results of Aug 7, 2025, 41 days before results of Oct 30, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $751.99 on Sep 19, 2025, 20% above its 52-week low and 19% below its high, after a 17% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $932.06 (Oct 11, 2024), 41% of the way up, from 242 adjusted closes. 30 trading days earlier: $640.86 on Aug 7, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Inluriyo on Sep 25, 2025, 6 days after this trade.
New drug application approved. Active ingredient: Imlunestrant Tosylate. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.1% | +0.5% | +1.7% |
| 30 days | +9.9% | +1.3% | +8.6% |
| 90 days | +44.1% | +3.3% | +40.9% |
| 180 days | +21.9% | −1.2% | +23.1% |
| 365 days | +54.1% | +15.8% | +38.3% |
Past results only. Not a forecast.
Fund moves
12 tracked managers disclosed the same change for Q3 2025. Among this manager's largest new positions for Q3 2025.
Fund moves
121 tracked managers disclosed the same change for Q3 2025. From a 13F filed Oct 22, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
100 tracked managers disclosed the same change for Q3 2025. From a 13F filed Oct 21, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.